Oxygenta Pharmaceutical Ltd
Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.
- Market Cap ₹ 310 Cr.
- Current Price ₹ 87.4
- High / Low ₹ 87.4 / 25.0
- Stock P/E
- Book Value ₹ -6.18
- Dividend Yield 0.00 %
- ROCE -42.2 %
- ROE %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 33.7%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 2.43 | 6.12 | 12.32 | 8.15 | 12.87 | 20.51 | 13.72 | 52.03 | 60.52 | 30.99 | 39.64 | 45.40 | |
1.45 | 5.89 | 10.24 | 16.49 | 12.99 | 16.87 | 22.54 | 21.59 | 48.19 | 59.05 | 38.11 | 49.34 | 53.26 | |
Operating Profit | -1.45 | -3.46 | -4.12 | -4.17 | -4.84 | -4.00 | -2.03 | -7.87 | 3.84 | 1.47 | -7.12 | -9.70 | -7.86 |
OPM % | -142.39% | -67.32% | -33.85% | -59.39% | -31.08% | -9.90% | -57.36% | 7.38% | 2.43% | -22.98% | -24.47% | -17.31% | |
-0.22 | 0.23 | 0.01 | 0.00 | 0.62 | 1.36 | 0.31 | 4.02 | 2.28 | 0.55 | -0.71 | 0.08 | 0.23 | |
Interest | 0.00 | 0.01 | 0.21 | 0.51 | 0.60 | 0.90 | 0.75 | 1.09 | 1.78 | 0.92 | 1.49 | 1.59 | 1.70 |
Depreciation | 0.00 | 0.86 | 2.53 | 0.82 | 0.90 | 0.94 | 1.02 | 1.00 | 1.20 | 1.59 | 2.05 | 2.66 | 2.81 |
Profit before tax | -1.67 | -4.10 | -6.85 | -5.50 | -5.72 | -4.48 | -3.49 | -5.94 | 3.14 | -0.49 | -11.37 | -13.87 | -12.14 |
Tax % | 0.00% | 4.63% | -10.80% | 0.00% | 1.57% | 1.12% | -6.88% | -2.53% | 6.69% | 24.49% | 1.76% | -74.91% | |
-1.67 | -4.29 | -6.11 | -5.50 | -5.81 | -4.53 | -3.25 | -5.79 | 2.93 | -0.61 | -11.57 | -3.48 | -0.28 | |
EPS in Rs | -1.64 | -4.21 | -5.99 | -5.39 | -5.70 | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -1.04 | -0.05 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 32% |
5 Years: | 14% |
3 Years: | -9% |
TTM: | 57% |
Compounded Profit Growth | |
---|---|
10 Years: | 2% |
5 Years: | -2% |
3 Years: | % |
TTM: | 97% |
Stock Price CAGR | |
---|---|
10 Years: | 20% |
5 Years: | 64% |
3 Years: | 38% |
1 Year: | 194% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10.20 | 10.20 | 10.20 | 10.20 | 10.20 | 10.20 | 10.20 | 10.20 | 10.20 | 14.20 | 14.20 | 33.48 |
Reserves | -15.19 | -19.48 | -26.27 | -31.77 | -37.58 | -42.11 | -45.36 | -51.15 | -48.22 | -48.83 | -60.40 | -54.17 |
8.11 | 10.62 | 14.67 | 17.36 | 19.25 | 19.15 | 22.34 | 26.92 | 47.89 | 52.13 | 68.00 | 57.24 | |
13.66 | 16.85 | 19.49 | 23.98 | 27.20 | 29.73 | 33.98 | 32.65 | 24.00 | 13.67 | 32.47 | 26.64 | |
Total Liabilities | 16.78 | 18.19 | 18.09 | 19.77 | 19.07 | 16.97 | 21.16 | 18.62 | 33.87 | 31.17 | 54.27 | 63.19 |
12.36 | 15.75 | 11.55 | 12.80 | 12.45 | 12.29 | 11.90 | 11.42 | 16.31 | 19.98 | 27.91 | 29.36 | |
CWIP | 2.53 | 0.00 | 0.06 | 0.07 | 0.43 | 0.06 | 0.00 | 0.00 | 0.65 | 0.34 | 0.00 | 0.00 |
Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
1.84 | 2.39 | 6.43 | 6.85 | 6.14 | 4.57 | 9.21 | 7.15 | 16.86 | 10.80 | 26.31 | 33.78 | |
Total Assets | 16.78 | 18.19 | 18.09 | 19.77 | 19.07 | 16.97 | 21.16 | 18.62 | 33.87 | 31.17 | 54.27 | 63.19 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0.61 | -2.69 | -4.28 | 0.85 | 0.52 | 1.28 | -7.79 | -2.59 | -1.62 | -1.68 | -1.63 | -13.05 | |
-2.57 | -1.62 | 0.93 | -2.08 | -0.90 | -0.39 | -0.56 | -0.50 | -6.72 | -4.94 | -9.64 | -4.09 | |
3.77 | 3.73 | 3.42 | 1.17 | 0.39 | -0.90 | 8.36 | 3.19 | 8.67 | 6.33 | 11.22 | 17.13 | |
Net Cash Flow | 0.59 | -0.58 | 0.07 | -0.06 | 0.01 | -0.01 | 0.01 | 0.10 | 0.33 | -0.29 | -0.05 | -0.01 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 127.67 | 38.17 | 43.85 | 38.52 | 13.61 | 9.08 | 11.17 | 11.29 | 9.53 | 119.66 | 67.77 | |
Inventory Days | 33.18 | 83.74 | 40.95 | 121.67 | 57.34 | 120.99 | 99.57 | 120.67 | 56.27 | 178.02 | 149.35 | |
Days Payable | 10,164.70 | 1,799.72 | 666.60 | 599.27 | 395.51 | 203.16 | 189.76 | 137.41 | 49.93 | 361.50 | 249.18 | |
Cash Conversion Cycle | -10,003.84 | -1,677.80 | -581.80 | -439.09 | -324.55 | -73.09 | -79.02 | -5.45 | 15.87 | -63.82 | -32.05 | |
Working Capital Days | -1,575.66 | -616.09 | -454.47 | -511.90 | -430.80 | -155.54 | -261.25 | 5.89 | 14.60 | -26.62 | -13.44 | |
ROCE % | -70.05% | -187.89% | -0.88% | -46.56% | -42.23% |
Documents
Announcements
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
8 Oct - Information on loss and issuance of duplicate share certificates.
-
Detailed Public Statement
8 Oct - Open offer to acquire 96,16,000 equity shares at ₹40 each.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
3 Oct - Voting results of 31st AGM of Oxygenta Pharmaceutical Limited.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 3 Oct
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 3 Oct
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Products:[1]
Losartan potassium intermediate, Gabapentin intermediate, Antihypertensive drugs, Anti
cancer drugs, Antiulcer drugs, Antiretroviral drugs, Antihypertensive drugs, Antiviral drugs.